Efficacy and tolerability of Meratrim for weight management: a randomized, double-blind, placebo-controlled study in healthy overweight human subjects by Venkateshwarlu Kudiganti et al.
RESEARCH Open Access
Efficacy and tolerability of Meratrim for
weight management: a randomized,
double-blind, placebo-controlled study in
healthy overweight human subjects
Venkateshwarlu Kudiganti1*, Raveendra Ramamurthy Kodur1, Sushma Raveendra Kodur1,
Manjunath Halemane2 and Dheeraj Kumar Deep2
Abstract
Background: Meratrim is a blend of two plant extracts obtained from Sphaeranthus indicus flower heads and Garcinia
mangostana fruit rinds. Previous studies have demonstrated that Meratrim is effective for weight management in
obese individuals. The objective of this study was to assess the efficacy and tolerability of Meratrim in managing body
weight in healthy overweight subjects.
Methods: Sixty participants with a mean BMI of 28.3 kg/m2 were randomized into two groups receiving either 400 mg
of Meratrim twice daily or two identical placebo capsules for a period of 16 weeks. Subjects were asked to consume
about 2,000 kcal/day throughout the study period and walk 5 days a week for 30 min daily. The primary endpoint was
defined as the change in body weight from baseline to end of week 16 for the Meratrim group versus placebo. Fifty
seven subjects completed the trial.
Results: At study conclusion, statistically significant reductions in body weight (5.09 vs. 1.1 kg; p < 0.0001), BMI
(1.91 vs. 0.43 kg/m2; p < 0.0001), waist (9.97 vs. 3.71 cm; p < 0.001) and hip size (10.38 vs. 5.11 cm; p < 0.0001) were
observed in the Meratrim versus the placebo group. Additionally, a significant change in serum LDL (−14.79 vs. 6.25
mg/dL; p < 0.0001), triglycerides (−43.62 vs. -13.68 mg/dL; p < 0.001) and total cholesterol (−20.0 vs. -0.75 mg/dL;
p = 0.0002) was observed in the Meratrim cohort compared to the placebo. No supplementation related adverse
events were noted during the study.
Conclusions: The study findings suggest that Meratrim is well-tolerated and is an effective ingredient for weight
management in healthy overweight subjects.
Trial registration: CTRI/2014/07/004727; www.CTRI.nic.in
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Background
The World Health Organization has acknowledged that
obesity appears to be reaching epidemic proportions on
a global scale [1–3]. The worldwide socioeconomic im-
pact of this disease is estimated at approximately $2 tril-
lion dollars, equivalent in size to the socioeconomic cost
linked to cigarette smoking [4]. In light of this estimate,
there continues to be a strong need for systematic inter-
ventions (e.g., education, changes in food choices and
eating habits, exercise, dietary supplements, and phar-
maceuticals) aimed at slowing this disease’s unabated
growth.
Earlier studies reported that an herbal formulation
(Meratrim) consisting of extracts of the flower heads
from Sphaeranthus indicus and the fruit rinds of Garci-
nia mangostana demonstrated significant weight loss
outcomes in two randomized, double-blind, placebo-
controlled clinical studies on obese subjects [5, 6]. An
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800 mg daily dose of this supplement resulted in statisti-
cally significant reductions in body weight, BMI, waist
and hip circumference that exceed those achieved via
diet and exercise alone. The blend’s significant effect on
body weight and anthropomorphic parameters occurred
as early as 2 weeks and continued to increase during the
8-week trial. Additionally, consuming the herbal blend
also yielded significant improvements in lipid and gly-
cemic serum profiles.
To evaluate the weight loss efficacy of Meratrim sup-
plement on healthy overweight subjects, we conducted a
16-week randomized, double-blind, placebo controlled
trial in healthy overweight individuals with an average
BMI of 28.3 kg/m2. The primary objective of our study
was to assess the weight loss efficacy and tolerability of
Meratrim in reducing body weight. We report herein
that consuming Meratrim increases weight loss that is
statistically significant versus the weight loss due to diet
and exercise alone, and that this ingredient is well toler-
ated. In addition, we also describe the possible molecular




Meratrim consisted of extracts from the flower heads of
Sphaeranthus indicus (S. indicus) and the fruit rinds of
Garcinia mangostana (G. mangostana). The extracts
were prepared using the method as previously described
[5–7]. Briefly, S. indicus flower heads were pulverized
and extracted first with methanol then with ethyl acetate
to form a thick paste. Separately, G. mangostana fruit
rinds were pulverized and extracted with 80:20 ratio of
methanol to water. The solvent was removed under vac-
uum, and the resulting flakes were milled. The S. indicus
paste and G. mangostana powdered extract were
blended together in 3:1 ratio then combined with excipi-
ents (55 % w/w) to produce Meratrim. Both 7-
hydroxyfrullanolide and α-mangostin served as internal
standards for monitoring the batch-to-batch consistency
of the S. indicus and G. mangostana extracts,
respectively.
Meratrim was manufactured in a CGMP certified facil-
ity (Laila Nutraceuticals, Vijayawada, India) and encap-
sulated in size zero hard gelatin maroon colored
capsules with the excipients microcrystalline cellulose
(SANCEL-W, NB Entrepreneurs, Nagpur, India) and
magnesium stearate (Magnesium stearate, Amishi Drugs
and Chemicals Private Limited. Ahmedabad, India), in a
batch type capsule filling equipment (MF-30, ACG PAM
Pharma Technologies Pvt. Ltd, Mumbai, India). Identical
placebo capsules contained only excipients were pre-
pared in the same facility. Both Meratrim and placebo
capsules were packaged in white, 100 cc HDPE screw
cap bottles and submitted to Clinical Quality Assurance
(QA) team. Study supplement bottles were stored at
room temperature, in a secure cabinet with access lim-
ited to the clinical QA team members until distributed.
Coded labels, prepared as per randomization code by
QA personnel, were affixed to the study bottles. Mera-
trim and placebo bottles were mixed, arranged in se-
quential order and submitted to the study site. Study
product labels conformed to all local and international
clinical trial requirements and guidelines. The study site
investigator, or his designate, maintained an inventory of
all investigational products received, dispensed, and
returned to the site by study participants during each
site visit.
Cell based studies
Cell culture and treatments
3T3-L1 mouse embryo fibroblasts and HepG2 human
hepatocellular carcinoma cells were obtained from
American Type Culture Collection (Manassas, VA) and
cultivated in DMEM supplemented with 10 % fetal bo-
vine serum (FBS) 100 U/ml penicillin, 100 μg/ml
streptomycin, 1 mM sodium pyruvate and 4.5 g/L D-
glucose. 3T3-L1 preadipocytes were differentiated to ma-
ture adipocytes as described previously [8]. For treat-
ments, the dry powdered Meratrim was dissolved in
DMSO and the final concentration of DMSO in the cul-
ture was 0.2 % (v/v) in all experiments. Matured adipo-
cytes or hepatocytes were treated with desired
concentration of Meratrim for various time periods; ve-
hicle control culture wells received 0.2 % DMSO only.
Adipogenesis assay
Equal number of cells was plated in each well of 24-well
culture plates. Cells were pre-treated with 5, 10 and
15 μg/ml of Meratrim for 2 h and followed by addition
of differentiation medium containing 500 nM insulin,
1.0 μM Dexamethasone and 0.5 mM isobutylmethyl-
xanthine (IBMX) for 48 h. Thereafter, cells were further
incubated with post differentiation medium (DMEM
containing 100 nM insulin) in presence or absence of
different concentrations of test samples for further
8 days. The control cultures received only 0.2 % (v/v)
DMSO as the vehicle. The remaining procedure was the
same as described earlier [8].
Lipolysis assay
The intracellular lipid break down efficacy of Meratrim
was evaluated by measuring the released glycerol in the
3T3-L1 culture supernatants. Briefly, equal number of
3T3-L1 preadipocytes was allowed to differentiate into
mature adipocytes in each well of 24-well culture plate
as stated in Adipogenesis assay method. Every culture
well contained 90–95 % differentiated cells with
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numerous intracellular vesicles visible under microscope.
Thereafter, the wells were washed two times with pre-
warmed Hank’s Balanced Salt Solution (HBSS). Washed
cells were treated 5, 10 and 25 μg/ml Meratrim in phe-
nol red free DMEM supplemented with 2 % Bovine
serum albumin (BSA) for 2 h. Cell culture supernatants
were clarified at 10,000 g for 5 min. at 4 °C. Released
glycerol content in the culture supernatants was mea-
sured following the protocol provided with Adipolysis
Assay Kit (Millipore, Billerica, MA).
Immunoblot assay
Briefly, the treated cells were washed twice with chilled
PBS and the cell lysates were prepared in a lysis buffer
[8]. The cell lysates were clarified at 14,000 g for 20 min
at 4 °C. The protein concentrations were estimated by
Bradford reagent.
Equal amount of proteins was resolved in SDS-PAGE.
Following SDS-PAGE, the electro-blotted nitrocellulose
membranes were reacted with relevant primary antibody
specific to AMPK, phospho-AMPK (Thr172), ACC,
phospho-ACC (Ser79), Fatty Acid Synthase and Actin
(Cell Signaling Technology, Boston, MA). Specific sig-
nals were detected with enhanced chemiluminescence
(Thermo scientific, USA) and the signal intensities were
captured in Gel Doc™ XR+ Imaging System and analyzed
using Image Lab™ 2.0 Software (BioRad, Hercules, CA).
Clinical study
Study design
This was a randomized, parallel group, double-blind,
placebo-controlled, 16-week intervention study, per-
formed from 30 August, 2014 to 23 February 2015, de-
signed to assess the efficacy of Meratrim in facilitating
weight loss in healthy, overweight individuals who exer-
cise and diet. The study was performed at a single clin-
ical center (Srinivasa Clinic & Diabetic Care Centre) in
Southern India under the management of the clinical re-
search organization D2L Clinical Solutions (Bangalore,
India). The clinical trial registration number is CTRI/
2014/07/004727. The study protocol was evaluated and
approved by the Bangalore Ethics Committee (Bangalore,
India) on 13 May 2014. The clinical center complied with
all relevant ICH-GCP, the Declaration of Helsinki (1996),
plus all applicable local government and institutional re-
search policies, procedures, and guidelines. The study was
conducted according to US and international standards of
Good Clinical Practice (FDA Title 21 CFR part 312 and
ICH guidelines).
Efficacy outcome measures, including weight, waist,
and hip circumference were recorded at all visits. Lean
body mass was assessed via Dual energy X-ray absorpti-
ometry (DEXA) at randomization and at the final study
visit (week 16). Both assessments were conducted after
overnight fasting. Medical monitoring included a phys-
ical examination and vital signs measurements at all
visits. Subject diaries and compliance cards were pro-
vided beginning at randomization through the final visit,
and collected at all follow up visits. Study product was
dispensed starting at the randomization visit through
week 12. Study supplement bottles were collected at all
follow up visits and unused capsules counted. Blood and
urine sample collections were obtained at screening,
weeks 4 and 8, and at study conclusion. Pregnancy testing
was done at screening and all follow-up visits starting at
visit 4 (week 4). Adverse events (AEs) were recorded using
the subject’s diary inputs plus a site visit questionnaire ad-
ministered by the study personnel at all visits.
Clinical endpoints
The primary endpoint for this clinical study was the re-
duction in body weight from baseline to the end of the
treatment period. Secondary endpoints include an-
thropometric measurements, such as body mass index
(BMI), waist and hip circumference, waist-to-hip ratio.
Additional secondary endpoints include changes in
serum lipid profile, increase in lean body mass and
serum levels of adiponectin, leptin, ghrelin and insulin.
Waist girth was measured as the smallest horizontal
girth between the costal margins and the iliac crests at
the end of normal expiration, while hip girth was mea-
sured at the greatest abdominal circumference at the
level of greater trochanters. In addition the Visual Ana-
log Scale (VAS) for appetite and the Profile of Mood
States-Short Form (POMS-SF) were used to assess sub-
ject appetite and mood, respectively [9, 10] Both ques-
tionnaires were administered after overnight fasting. All
clinical efficacy data was entered into the subjects CRF
by the clinical site coordinator delegated by principal in-
vestigator (PI). CRFs were reviewed, verified and signed
by the PI.
Subject recruitment
Sixty eligible subjects were recruited through inclusion
and exclusion criteria into the study (Table 1). Healthy
overweight adult men and women (21–50 years), who
were willing to adhere to a vegetarian or non-vegetarian
diet of approximately 2000 kcal/day consisting of 17 %
protein, 25 % Fat and 58 % carbohydrate and 30 min
walk for five days per week were enrolled in the study.
Individuals who presented with intractable obesity, a his-
tory of chronic diseases, or personal behaviors that
would confound the interpretation of results arising
from this study were excluded.
Randomization and blinding
Participants were randomized 1:1 using randomization
codes that were computer generated using a permuted
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block design consisting of 60 individuals. The
randomization code was generated by an independent
statistician using SPSS statistical software version 16.
The randomization codes were stored centrally in
opaque, sealed envelopes at the clinical site so they
could be opened by medical personnel in case of a
medical emergency. The randomization code was
broken after the database was locked.
Dosing regimen
Subjects were instructed to ingest one capsule (400 mg)
twice daily thirty minutes before breakfast and dinner.
Dosage forms were tested using HPLC methods devel-
oped by Laila Nutraceuticals (Vijayawada, India).
Prior and concomitant therapies
Use of any centrally acting anorectic nutraceuticals, drugs
or other agents that inhibit the absorption of nutrients or
promote weight loss were prohibited two weeks prior to
enrolment into the study. Enrolled subjects were not per-
mitted to use any concomitant medications without first
consulting with the study investigator. Based on the in-
vestigator’s discretion, the following OTC medications
were permitted - Cetirizine, Pantoprazole, Gelusil and
Nimesulide - in order to address any allergies, dyspepsia,
or transient aches and pain during the course of the study.
Compliance and safety
Subjects were instructed to bring their study supplement
bottles to each follow up visit. The number of remaining
Table 1 Inclusion and exclusion criteria
Inclusion Criteria
• Male or female subjects between 21 to 50 years of age.
• Subject with BMI range (27–32 kg/m2).
• Ability to understand the risks/benefits of the protocol.
• Female subjects of childbearing potential must be using a medically acceptable form of birth control. Female subjects of non-childbearing potential
must be amenorrheic for at least 1 year or had a hysterectomy and/or bilateral oophorectomy.
• Willingness to participate in a walking-exercise program (30 min per day) during the course of the study.
• Subject agrees to consume a vegetarian/non-vegetarian diet of approximately 2000 kcal/day (17 % protein, 25 % Fat and 58 % carbohydrate).
• Subjects agree to come to study site in fasting condition for their weight measurement and other laboratory parameters examination in all the
scheduled visits.
• Subjects should be available for the entire duration of the study (6–8 months).
• Subject using other therapies for weight management including physiotherapy/ occupational therapy agrees to discontinue these therapies during
this study.
• Subject willing to go for DEXA analysis as per the scheduled visits during the study.
• Subjects agree to maintain the activity dairy.
• Subjects willing to give written informed consent and willing to comply with the trial protocol.
Exclusion Criteria
• Subjects suffered from intractable obesity, had defined weight limits or had experienced any recent, unexplained weight loss or gain.
• Subjects having history of underlying inflammatory arthropathy; septic arthritis; inflammatory joint disease; gout; pseudo-gout; Paget's disease; joint
fracture; acromegaly; fibromyalgia; Wilson's disease; ochronosis; hemochromatosis; heritable arthritic disorder or collagen gene mutations or
rheumatoid arthritis.
• Subjects having history of asthma, cardiovascular diseases, thyroid disease, coagulopathies, hypertension, congestive heart failure.
• Subjects having history of diabetes (Type I or Type II) - except other than the subject having the pre-diabetes condition with the fasting blood
glucose between 100 to 125 mg/dl or random blood glucose≥ 140–199 mg/dl.
• Subject with Hyperuricemia (males > 480 μmol/L, females > 450 μmol/L).
• Subjects having abnormal liver or kidney function tests (ALT or AST > 2 times the upper limit of normal; elevated Creatinine, males > 125 μmol/L,
females > 110 μmol/L).
• Subjects having abnormal findings on complete blood count.
• Subjects with HIV Positive.
• Subjects having history of high alcohol intake (>2 standard drinks per day).
• Pregnant, breast feeding or planning to become pregnant during the study.
• Subjects having history of psychiatric disorder that may impair the ability of subjects to provide written informed consent.
• Any other condition that, in the opinion of the investigator, would adversely affect the subject's ability to complete the study or its measures.
• Subjects participated in any investigational drug study within thirty (30) days prior to screening.
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capsules in each bottle was recorded. Subjects also com-
pleted a dairy indicating daily consumption of study sup-
plement and listing of any adverse events that might
have occurred. Safety assessments were done at each
clinical visit by the PI and recorded into each subject’s
CRF by clinical study staff. CRFs were reviewed and
signed by the PI. Adverse events were characterized ac-
cording to standardized nomenclature set by MedDRA.
Study evaluations
Subject weights were obtained using a calibrated scale
(AVON Corporation Ltd, Model No: APD802). Subject
activity levels were assessed using a Digiwalker SW-701
pedometer (Yamax, San Antonio, TX). Specimens were
analyzed using the Prietest clinical chemistry analyzer
(ROBONIK INDIA PVT LTD, Mumbai, India). DEXA
measurements were carried out using the enCORE®
based X-ray Bone Densitometer; Lunar Prodigy Series
(GE Medical Systems, Chakan, Pune, India). Leptin, adi-
ponectin and insulin were quantitatively estimated in the
serum samples using specific EIA based methods. Leptin
(EZHL-80SK), Adiponectin (442307) and Insulin
(IS130D) ELISA kits were procured from EMD Millipore
Corporation (Billerica, MA), BioLegend Inc. (San Diego,
CA) and Calbiotech Inc. (Spring Valley, CA), respect-
ively. The assay procedures to estimate the biomarkers
were essentially the same as recommended by the re-
spective vendors. Briefly, the specific monoclonal anti-
body coated 96-well plates were reacted with the serum
samples. The specific antibody-antigen bindings were
probed with biotinylated detection antibody and
followed by streptavidin conjugated horseradish peroxid-
ase enzyme. Finally, the color developments were re-
corded in a spectrophotometer (SpectraMax M5e,
Molecular Devices, Sunnyvale, CA) and the data were
analyzed using SoftMax Pro v5.4. The assay sensitivities
of Leptin, Adiponectin and Insulin are 0.2 ng/ml,
0.086 ng/ml and 0.4777μIU/ml, respectively.
Statistical analyses
All subjects randomized into the study and participated in
at least one post-baseline assessment were included in all
efficacy assessments (ITT). Missing observations were im-
puted using the last observation carried forward (LOCF)
approach. Additional analyses of the primary endpoints
were carried out on a per protocol basis and included com-
pleters free of protocol violations. Between group differ-
ences were determined using ANCOVA with baseline set
as the covariate. The unpaired and paired t tests were used
to test for between group and within group differences in
those cases where the data was normally distributed. Statis-
tical significance was set at ≤0.05. Power calculations, using
previously published efficacy data [5, 6], allowed us to con-
clude that 20 completers per cohort was sufficient to
achieve 80 % power to detect outcome differences in weight
loss between the groups, assuming a two-sided significance
level of 0.05. Thirty subjects per treatment group were cal-
culated to provide more than 90 % power under identical
analytical conditions. Based on these estimates, and assum-
ing a 40 % screen failure rate, we anticipated that we would
need to screen 100 individuals to obtain 60 volunteers (30
subjects per group), the targeted sample size for this study.
In practice, we screened a total of 82 subjects to achieve
the targeted number of randomized volunteers required.
Subjects without a baseline efficacy assessment were ex-
cluded from the analysis of that efficacy variable. Safety
analyses were done on an ITT basis. Statistical analyses
were generated using SAS version 9.2.
Results
Demographics and baseline characteristics
Table 2 summarizes the demographics of the 60 subjects
that were eligible for efficacy and safety analyses. The
summary includes the subject’s weight, BMI, waist and
hip size, as well as their blood biochemistry status. Out
of 82 individuals screened, 60 subjects who met the
study’s eligibility criteria were randomized to placebo or
Meratrim (n = 30 per group).
Subject dropouts
Three individuals dropped out from the study. Two were
in the placebo cohort, one in the Meratrim supplemen-
tation group. The placebo group dropouts occurred at
Table 2 Demographic and Baseline characteristics of the
subjects eligible for the trial
Characteristics Placebo Meratrim
(n = 30) (n = 30)
Sex ((n) male + (n) female) 14 M + 16 F 10 M + 20 F
Age (years) 39.47 ± 1.73 36.63 ± 1.64
Height (meters) 1.65 ± 0.017 1.63 ± 0.02
Body weight (kg) 76.56 ± 1.64 75.93 ± 1.91
Body mass index (kg/m2) 28.20 ± 0.24 28.48 ± 0.25
Waist circumference (cm) 103.30 ± 1.53 102.00 ± 1.59
Hip circumference (cm) 108.70 ± 1.88 108.60 ± 1.59
Waist/Hip ratio 0.96 ± 0.017 0.94 ± 0.013
Triglycerides (mg/dL) 200.50 ± 8.16 194.20 ± 8.96
Total cholesterol (mg/dL) 184.90 ± 6.18 168.80 ± 5.37
LDL (mg/dL) 108.20 ± 5.97 94.67 ± 4.73
HDL (mg/dL) 36.60 ± 0.42 35.27 ± 0.51
LHR 2.94 ± 0.15 2.68 ± 0.12
VLDL (mg/dL) 40.13 ± 1.67 38.83 ± 1.78
Fasting blood glucose (mg/dL) 99.47 ± 1.82 95.60 ± 1.99
Values represent mean ± SE
LDL low-density lipoproteins; HDL high-density lipoprotein; LHR LDL/HDL ratio;
VLDL very low-density lipoproteins
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visits four and six and were due to one subject deciding
to discontinue participating in the study, while the other
was due to the subject’s relocation and not being able to
visit the clinic. The single subject dropout for the Mera-
trim group occurred at visit 4 and was also due to the
subject’s relocation away from the study site. The num-
ber of completers in placebo and Meratrim group was
28 and 29, respectively.
Study compliance
Compliance with daily dosing of study capsules exceeded
95 % for all cohorts (data not shown). Readouts from
the individual pedometers showed that the Meratrim
and placebo groups, walked similar average distances per
day during the course of this study. A detailed review of
each subject diary showed that both groups complied to
a high extent with the recommended diet (data not
shown).
Weight loss
By the end of the study (16 weeks), the Meratrim sup-
plemented cohort presented an average weight loss of
5.09 kg in sharp contrast to the 1.1 kg average loss noted
in the placebo group (p < 0.0001; Table 3). It is interest-
ing to note that Meratrim supplemented group experi-
enced gradual weight reduction from the second week of
commencement of the study. At the end of the trial,
Meratrim group demonstrated 6.7 % body weight reduc-
tion; in contrast, placebo recorded only 1.4 % body
weight reduction (Table 3). Meratrim supplemented
group experienced a net BMI reduction of 1.91±0.13 kg/
m2 (28.46±0.25 and 26.55±0.25 kg/m2 at baseline and at
week 16, respectively); in comparison, at the end of the
study the placebo showed a reduction of BMI only 0.43
±0.19 kg/m2. At termination, intergroup analysis be-
tween the net changes of BMI (baseline vs. termination)
was significant (p<0.0001).
DEXA
At trial initiation, all study participants have undergone
DEXA scan to measure body fat percentage but only 22
subjects (eleven subjects in each group) have agreed for
the scan at the final evaluation. We consider that this
small group size cannot be a proper representative of
the overall population. This event can be classified as
minor protocol deviation, as it does not influence the
data constituting the primary outcome of the study, or
subject well-being; and was reported to the IEC as stipu-
lated by their bylaws and the conditions under which ap-
proval for this study was granted (data not presented).
Changes in anthropometric parameters
Statistically significant decreases in both hip and waist size
were noted as early as four weeks (Table 4). By study con-
clusion, the average waist size of subjects supplemented
with Meratrim decreased by 9.97 cm as compared to
3.71 cm for subjects consuming placebo (p < 0.001). Hip
size also decreased significantly (10.38 cm, p < 0.0001) by
the end of the study. The reduction in hip size, as was
noted for weight loss, underwent a significant increase in
magnitude after eight weeks of supplementation. None-
theless, the change in hip size was statistically significant
versus placebo at as early as 4 weeks (3.14 cm vs. 2.21 cm,
p < 0.035). No statistically significant change in the waist
to hip ratio was noted for this study as both parameters
changed similarly during the course of this research.
Change in biochemistry biomarkers
Consistent with the previous observations [5], the
present study demonstrated that Meratrim supplementa-
tion significantly reduced the serum levels of triglycer-
ides (−43.6 mg/dL vs −13.7 mg/dL; p < 0.001) and total
cholesterol (−20.0 mg/dL vs −0.8 mg/dL; p < 0.002) over
the reductions obtained by diet and exercise alone
(Table 5). Significant reductions in serum levels of LDL
(p < 0.0001) and VLDL (p = 0.011) were also observed
for the Meratrim supplemented cohort over placebo.
Interestingly, at the end of the study, Meratrim provided
an increase in serum HDL level by 2.03±0.75 mg/dL,
whereas, in placebo HDL level was reduced by 1.96
±0.48mg/dL, and this improvement is statistically signifi-
cant (p < 0.0001) (Table 5). Changes in fasting glucose
Table 3 Reduction in body weight in Meratrim and placebo groups over 16 week study period
Parameter Reduction Weeks Placebo Meratrim Net reductiona,b P value
(n = 28) (n = 29)
Body weight (kg) 2 0.42 ± 0.18 0.51 ± 0.16 0.09 (0.1 %) 0.749
4 0.64 ± 0.29 1.53 ± 0.20 0.89 (1.2 %) 0.048*
8 1.26 ± 0.40 2.10 ± 0.25 0.84 (1.1 %) 0.190
12 1.19 ± 0.43 3.14 ± 0.28 1.95 (2.6 %) 0.002*
16 1.10 ± 0.46 5.09 ± 0.38 3.99 (5.3 %) <0.0001*
Values represent mean ± SE
*Significant difference between Meratrim and placebo group mean values calculated using ANCOVA with baseline as covariate
aNet reduction =Meratrim minus placebo
bNumbers in parenthesis represents the % net reduction from baseline for Meratrim group
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levels in both the groups from the baseline were not sig-
nificant (Table 5).
VAS-appetite & POMS-short form questionnaires
At study conclusion, the mean score of Visual Analog
Scale (VAS) for appetite in placebo was increased by 207.4
units, while the score in Meratrim supplemented group
was increased by only 23.6 units (Table 6). The intergroup
analyses on the difference of VAS-appetite score at the
end of the study reveal that Meratrim supplemented
group experienced a significantly (p < 0.001) lower VAS-
appetite score, in comparison with the placebo (Table 6).
A statistically significant reduction in the mean total mood
disturbance (TMD) score was observed in subjects supple-
mented with Meratrim over placebo (72.89 versus 39.76;
p < 0.0001). This decline in TMD is significant after 16 weeks
of Meratrim supplementation (Table 6). Compared to base-
line, the reduction in TMD scores was 46.93 % and 13.52 %
for Meratrim and placebo group, respectively.
Serum biomarkers
At study conclusion we did not obtain any statistically
significant changes in adiponectin, leptin, ghrelin or in-
sulin levels (Table 7). Despite the lack of statistical sig-
nificance, we did note some interesting trends. In the
case of adiponectin, Meratrim consumption resulted in
an average increase of 398.2 ng/ml while the placebo
group presented with a mean reduction of 1,030.2 ng/mL.
These changes are consistent with our previous observa-
tions [5]. Serum leptin and ghrelin levels declined similarly
for both the Meratrim and the placebo groups over their
respective baseline levels, an effect that may be due to im-
proved diet and to increased exercise. At study conclusion,
insulin levels increased similarly for both groups.
In vitro anti-adipogenic efficacy
Anti-adipogenic efficacy of Meratrim was investigated
in 3T3-L1 adipocytes at in vitro conditions. Mouse pre-
adipocyte 3T3-L1 cells were differentiated in presence
or absence of 5, 10 and 15 μg/ml Meratrim as indi-
cated. Oil Red O lipid staining revealed that Meratrim
reduced intracellular lipid accumulation in a dose-
dependent manner (Fig. 1a). Quantitative analyses
Table 4 Reduction in waist and hip circumference in Meratrim and placebo groups over 16 week study period
Parameter Reduction Weeks Placebo Meratrim Net reductiona,b P value
(n = 28) (n = 29)
Waist size (cm) 2 1.07 ± 0.34 1.45 ± 0.25 0.38 (0.4 %) 0.339
4 2.18 ± 20.39 3.38 ± 0.37 1.20 (1.2 %) 0.016*
8 2.82 ± 0.53 5.14 ± 0.49 2.32 (2.3 %) 0.001*
12 3.29 ± 0.58 6.83 ± 0.58 3.54 (3.5 %) <0.001*
16 3.71 ± 0.70 9.97 ± 0.73 6.26 (6.2 %) <0.001*
Hip size (cm) 2 1.04 ± 0.27 1.62 ± 0.26 0.58 (0.5 %) 0.109
4 2.21 ± 0.37 3.14 ± 20.41 0.93 (0.9 %) 0.035*
8 3.61 ± 0.55 4.45 ± 20.51 0.84 (0.8 %) 0.112
12 4.32 ± 0.58 6.55 ± 0.63 2.23 (2.1 %) 0.002*
16 5.11 ± 0.69 10.38 ± 0.85 5.27 (4.9 %) <0.0001*
Values represent mean ± SE
*Significant difference between Meratrim and placebo group mean values calculated using ANCOVA with baseline as covariate
aNet reduction =Meratrim minus placebo
bNumbers in parenthesis represents the % net reduction from baseline for Meratrim group
Table 5 Changes in biochemical parameters after 16 weeks of
supplementation
Parameter Placebo Meratrim P value
(n = 28) (n = 29)
Liver function
SGOT (U/L) −1.89 ± 0.83 −1.66 ± 0.97 0.2999
SGPT (U/L) −2.22 ± 0.85 −3.65 ± 0.94 0.0181
Renal function
BUN (mg/dL) −1.48 ± 0.26 −1.65 ± 0.29 0.1938
Creatinine (mg/dL) −0.15 ± 0.03 −0.15 ± 0.03 0.7998
Metabolic panel
Triglycerides (mg/dL) −13.68 ± 5.17 −43.62 ± 6.74 <0.001*
Cholesterol (mg/dL) −0.75 ± 5.10 −20.00 ± 2.88 0.0002*
LDL (mg/dL) 6.25 ± 4.79 −14.79 ± 2.93 <0.0001*
HDL (mg/dL) -1.96±0.48 2.03±0.75 <0.0001*
LHR 0.35 ± 0.14 −0.49 ± 0.11 <0.0001*
VLDL (mg/dL) −5.04 ± 1.16 −7.24 ± 1.08 0.011*
Fasting glucose (mg/dL) −10.64 ± 2.05 −9.41 ± 1.13 0.8926
Values represent mean ± SE
BUN Blood Urea Nitrogen, SGOT Serum Glutamic Oxaloacetic Transaminase;
SGPT Serum Glutamic-Pyruvic Transaminase; LDL low-density lipoproteins; HDL
high-density lipoprotein; LHR LDL/HDL ratio; VLDL very
low-density lipoproteins
*Significant difference between Meratrim and placebo group mean values
calculated using ANCOVA with baseline as covariate
Kudiganti et al. Lipids in Health and Disease  (2016) 15:136 Page 7 of 11
indicated that in comparison with the vehicle (0.2 %
DMSO) treated cultures, Meratrim treatment exhibited
16.34 % ± 3.09 (p = 0.0195), 25.76 % ± 4.18 (p = 0.0071)
and 41.77 % ± 6.76 (p = 0.0001) inhibition in adipogene-
sis at 5, 10, 15 μg/mL, respectively (data not shown).
In addition, Meratrim exhibited a dose dependent in-
crease of intracellular lipolytic efficacy (measured as gly-
cerol secretion) in matured 3T3-L1 adipocytes (Fig. 1b).
Mature adipocytes treated with 5, 10, 25 μg/mL Mera-
trim produced 9.54 ± 0.96, 11.49 ± 1.12 and 14.52 ±
1.02 μg/mL glycerol, respectively; whereas, glycerol con-
tent in the control culture medium was 7.83 ± 1.35 μg/
mL. Therefore, Meratrim dose-dependently increased
glycerol production in adipocyte cultures (in comparison
with control) by 20.76 % (p = 0.0623), 46.75 % (p =
0.0091) and 85.43 % (p = 0.0018), respectively.
Meratrim down-regulates fatty acid synthase
Fatty acid synthase (FAS) is the key enzyme for de novo
lipogenesis in liver and fat cells [11]. Immunoblot exper-
iments demonstrate that Meratrim treatment reduced
FAS protein expression in 3T3-L1 adipocytes. Densito-
metric analyses on normalized FAS protein expression
reveal that Meratrim down regulates the intracellular en-
zyme expression by 34.3 % in 30 min (Fig. 2).
Meratrim up-regulates AMP Activated Protein Kinase
(AMPK) and Acetyl CoA Carboxylase (ACC)
Phosphorylation
To examine the effect of Meratrim in hepatocytes, we
treated the HepG2 cells with Meratrim at different time
periods as indicated. Immunoblot experiments reveal
that Meratrim phosphorylates AMPK at Thr172 in
HepG2 human hepatocytes, with no change in protein
level detected using antibody specific to the un-
phosphorylated protein. Subsequently, immunoblot ex-
periments also revealed that ACC, the target protein of
AMPK has also phosphorylated at Ser79 (Fig. 3). To-
gether, these observations confirm that Meratrim acti-
vates AMPK in HepG2 hepatocytes.
Safety assessments
A statistically significant decrease in SGPT levels were
noted in the Meratrim cohort versus the placebo. As this
change was within the physiologically normal range for
SGPT, we anticipate that there is no clinical relevance.
No additional differences were seen in the liver or the
kidney function panel for both the study groups
(Table 5).
No serious adverse events were reported in this trial
(Table 8). Nine minor adverse events occurred in the
placebo group, while seven were confined to the Mera-
trim group. These minor adverse events in the Meratrim
group included dyspepsia, acidity, nausea, and gastritis.
It was the PI’s medical opinion that none of these ad-
verse events were related to consumption of study sup-
plement. The adverse events reported for the placebo
group include skin rash, itching, headache, giddiness,
gastritis and dyspepsia, and feet swelling.
Discussion
We assessed the ability of Meratrim to manage weight
loss in healthy overweight subjects whose average BMI
was 28.3 kg/m2. The results presented herein demon-
strate that individuals consuming Meratrim experienced
greater weight loss and reductions in waist and hip size
compared to individuals consuming placebo. The Mera-
trim supplemented group got benefit by losing an aver-
age body weight of 5.09 kg at the end of the study,
which equals to 6.7 % of their mean body weight at the
baseline. As all participants in this study were counseled
on diet control and exercise, and the subject diaries and
pedometer data showed similar levels of compliance, we
conclude that the weight loss attributable to Meratrim
Table 6 Mood and appetite scores after 16 weeks of supplementation
Parameter Week Placebo Meratrim P value
(n = 28) (n = 29)
Total Mood Disturbance (TMD) 0 84.29 ± 8.210 74.93 ± 10.93 <0.001*
16 72.89 ± 10.31 39.76 ± 15.54
Total VAS Score 0 170.4 ± 28.58 229.8 ± 51.31 <0.001*
16 377.8 ± 58.01 253.4 ± 45.46
Values represent mean ± SE
*Significant difference between Meratrim and placebo group calculated using ANCOVA with baseline as covariate
Table 7 Changes in serum biomarkers after 16 weeks of
supplementation
Parameter Placebo Meratrim P value
(n = 28) (n = 29)
Adiponectin (ng/mL) −1030.2 ± 884.8 398.2 ± 1396.6 0.3940
Leptin (ng/mL) −15.49 ± 2.83 −18.32 ± 2.56 0.4620
Ghrelin (pg/mL) −35.92 ± 29.22 −39.79 ± 19.92 0.9138
Insulin (μIU/mL) 5.65 ± 2.31 8.44 ± 2.66 0.4336
Values represent mean ± SE
p values from unpaired t test between groups and variable sample size
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consumption is incremental to the weight loss obtained
via diet and exercise alone.
In this study we tested whether Meratrim consump-
tion by overweight individuals might impact their blood
glucose and lipid levels similar to what we previously re-
ported [5]. We found that Meratrim reduced blood
levels of triglyceride and total cholesterol in a statisti-
cally significant and a clinically relevant manner. How-
ever, unlike our previous results we did not observe an
impact on blood glucose levels despite an increase in
adiponectin levels, which has been shown to inversely
correlate with reductions in blood glucose levels [13,
14]. This was not a surprising outcome. In prior work,
the obese population we employed presented with fast-
ing blood glucose levels that ranged from 107 mg/dL to
109 mg/dL, clearly above the normal range for this
marker and indicative of prediabetes. Meratrim supple-
mentation reduced fasting glucose levels from 109 mg/dL
to 96 mg/dL after usage for two months [13, 14]. In the
present study, the fasting glucose levels were only in the
high end of the normal range and declined similarly for
both cohorts by study conclusion. In our previous work,
Meratrim supplementation also led to a statistically
Fig. 1 a Meratrim reduces lipid accumulation in 3T3-L1 adipopcytes. 3T3-L1 cells were allowed to differentiate in absence or presence of different
concentrations of Meratrim, and the cells were stained with Oil Red O. Photomicrographs show intracellular lipid staining in vehicle (0.2 % DMSO), and
5, 10, 15 μg/ml Meratrim treated cells in i, ii, iii and iv, respectively. b Meratrim enhances lipolysis in 3T3-L1 adipocytes. Differentiated 3T3-L1 adipocytes
were incubated with 5, 10, 25 μg/ml Meratrim for 2 h. Vehicle treated control cultures received only 0.2 % DMSO. Each bar represents
mean (μg/ml) ± SD of released glycerol. n = 5. * p < 0.05, ** p < 0.005 vs. vehicle
Fig. 2 Meratrim down regulates Fatty acid synthase (FAS) protein
expression in 3T3-L1 adipocytes. 3T3-L1 mature adipocytes were
treated with 10 μg/ml Meratrim for indicated time periods.
Representative immuno blots depict protein expression of FAS in
respective treatments as indicated, actin protein was evaluated as
the internal control. Each protein expression was measured
densitometrically and normalized with actin expression. The
normalized expressions FAS protein is represented as bar diagram
Fig. 3 Meratrim up regulates AMPK phosphorylation in HepG2
human hepatocytes. HepG2 cells were treated with 10 μg/ml
Meratrim for indicated time periods, Protein expressions of AMPK/
phospho-AMPKThr172 and ACC/phospho-ACCSer79 have been
estimated in cell lysate proteins using immunoblot assay. Expression
of actin protein was evaluated as the internal control
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significant improvement in serum adiponectin levels [5].
However, while we did observe an increase in adipo-
nectin levels, it was not significantly different when
compared with the placebo group. We strongly be-
lieve that these differences in outcome are due to
tangible, biochemical differences that exist between
the previously studied population, and the one we re-
port on herein [12]. These differences may also ac-
count for the lack of statistically significant changes
in ghrelin and leptin levels. Although, the improve-
ments are not statistically different, the trends suggest
that Meratrim helps to control hunger and satiety sig-
naling. Interestingly, we also observed that Meratrim
supplementation increased serum insulin level by
2.7μIU/ml (over placebo). This indicates that Meratrim
might increase beta cell function and helps in lowering
the risk of diabetes.
In line with the significant reduction in body weight
noted for the Meratrim cohort, we also observed a sta-
tistically significant change in this group’s waist and hip
sizes. By study conclusion, the net reductions in hip and
waist size were 4.9 % and 6.2 % of baseline values, re-
spectively. However, these changes did not impact the
waist-to-hip ratio sufficiently at study conclusion to
achieve statistical significance.
Both emotional well-being and psychosocial function-
ing are greatly affected by obesity, and weight reduction
has been shown to improve both of these mental states
[15–19]. Consistent with these findings, we found that
quality of life parameters, as measured by the Profile of
Moods Short Form, improved significantly (47 %) for
subjects consuming the herbal supplement. Interestingly,
at the end of the study the VAS appetite level in Mera-
trim group was significantly lowered in comparison with
the placebo group. These observations are strongly in
line with the leptin and ghrelin levels in serum, which
showed they were lower for the Meratrim cohort as
compared to the placebo group. These observations to-
gether strengthen the fact that Meratrim improves emo-
tional well-being and provides better control in hunger/
satiety balance in healthy overweight individuals.
At study conclusion we were unable to obtain sufficient
DEXA data to determine whether the ingestion of Mera-
trim resulted in a loss of lean or fat body mass. This
protocol deviation was deemed as minor as this was not a
primary outcome of this study. It was reported to the IEC
as required by their bylaws. Root cause analyses deter-
mined that some subjects during baseline evaluation expe-
rienced DEXA as a tedious process and were reluctant to
undergo the same process at 16 week DEXA scan.
In vitro experiments in cellular models demonstrate
that Meratrim inhibits adipogenic differentiation and
boosts lipid breakdown in mature fat cells. Earlier stud-
ies demonstrate that nutrients and hormones control
lipogenesis in adipocytes through directly regulating the
key enzymes of the lipogenic pathway [20, 21]. Acetyl
CoA Carboxylase (ACC) and Fatty acid synthase (FAS)
are the crucial enzymes in de novo lipogenesis, catalyz-
ing the sequential enzymatic steps in the conversion of
acetyl-CoA to malonyl-CoA to palmitate, respectively.
After a series of reactions, palmitate is further converted
into complex fatty acids. However, Fatty acid synthase
(FAS) is the key rate-limiting enzyme for de novo lipo-
genesis [22]. Our experiments demonstrate that Mera-
trim has significant potential to down regulate FAS
synthesis and to phosphorylate ACC at Ser79. ACC is
deactivated upon its phosphorylation at Ser79 by acti-
vated AMPK (phosphorylated at Thr172) [23, 24]. Inter-
estingly, immunoblot experiment demonstrates that
Meratrim phosphorylates AMPK at Thr172 in hepato-
cytes; this clearly indicates that Meratrim activates
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AMPK. AMPK activation is associated with the stimula-
tion of fatty acid oxidation, glucose uptake by muscle
cells [25–28], inhibition of cholesterol and triglyceride
synthesis [29]. AMPK activating potential of Meratrim
might be the basis of significant reduction in serum tri-
glyceride and cholesterol of the active group in the
present study. In summary, our observations together
strongly suggest that Meratrim inhibits de novo lipogen-
esis process and increases fat burning through beta oxi-
dation. These evidences provide strong support in favor
of the possible molecular mechanism underlying the
anti-obesity effect of Meratrim. In addition, our observa-
tions also suggest that Meratrim helps in maintaining
healthy lipid profile in overweight individuals.
Conclusion
We previously showed that Meratrim did not impact any
clinical chemistry biomarkers which assessed the physio-
logical health and functionality of the liver, the kidneys,
the heart, or blood. These observations have been con-
firmed in the current trial. These results add to the grow-
ing body of evidence which suggests that Meratrim is well
tolerated and has a broad-spectrum safety based on a bat-
tery of toxicological studies. In conclusion, the results pre-
sented herein validate that Meratrim is a well-tolerated
and effective ingredient for weight management in healthy
overweight individuals over a 16-week study period.
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